Direct T-cell Inhibition and Agents Targeting T-cell Migration and Chemotaxis

Lymphocyte depletion and blockade of T-cell activation and trafficking serve as therapeutic strategies for an enlarging number of immune-mediated diseases and malignancies. This review summarizes the infection risks associated to monoclonal antibodies that bind to the alpha chain of the interleukin-2 receptor, the cell surface glycoprotein CD52, and members of alpha 4- and beta 2-integrin families acting as cell-adhesion molecules. An outline of the mechanisms of action, approved indications and off-label uses, expected impact on the host immune response, and available clinical evidence is provided for each of these agents.